Início › Linfoma Difuso de Grandes Células B › Texas › Houston
Ensaios clínicos de Linfoma Difuso de Grandes Células B em Houston, TX
17 estudos para Linfoma Difuso de Grandes Células B estão buscando participantes em locais em Houston e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecrutandoEstudo observacional
- Texas Children's Hospital, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecrutandoFase 1/2
- Md Anderson Cancer Center, Houston
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecrutandoFase 3
- Houston Methodist Cancer Center ( Site 0154), Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecrutandoFase 1
- Baylor College of Medicine, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecrutandoFase 1
- MD Anderson Cancer Center, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RecrutandoFase 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RecrutandoFase 1
- Md Anderson Cancer Center, Houston
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RecrutandoFase 2
- MD Anderson Cancer Center, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RecrutandoFase 1/2
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecrutandoFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecrutandoFase 3
- MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
RecrutandoFase 1
- The University of TX MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
RecrutandoFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RecrutandoFase 1
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RecrutandoFase 1
- MD Anderson Cancer Center, Houston
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RecrutandoFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
RecrutandoFase 1
- MD Anderson Cancer Center, Houston
Ensaios de Linfoma Difuso de Grandes Células B em outras cidades
- New York City, NY21 estudos
- Baldwin Park, CA19 estudos
- Chicago, IL18 estudos
- Los Angeles, CA17 estudos
- Boston, MA16 estudos
- Milwaukee, WI16 estudos
- Philadelphia, PA15 estudos
- Portland, OR15 estudos
- Durham, NC14 estudos
- Nashville, TN14 estudos
- Dallas, TX13 estudos
- Salt Lake City, UT12 estudos
Outros estudos em Houston
- Câncer de Pulmão de Não Pequenas Células145 estudos
- Câncer de Mama126 estudos
- Câncer (todos os tipos)121 estudos
- Câncer Metastático104 estudos
- Câncer Colorretal102 estudos
- Câncer de Ovário90 estudos
- Leucemia Mieloide Aguda85 estudos
- Câncer de Pulmão78 estudos
- Câncer de Próstata76 estudos
- Câncer Endometrial68 estudos
- Câncer de Pâncreas62 estudos
- Melanoma59 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 2 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.